Information non disponible
Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trialArticle de revue
Clin Transl Radiat Oncol, 40 , 2023, ISSN: 2405-6308.
Commissioning of an intra-operative US guided prostate HDR system integrating an EM tracking technologyArticle de revue
Brachytherapy, 20 (6), 2021.
Performance of an enhanced afterloader with electromagnetic tracking capabilities for channel reconstruction and error detectionArticle de revue
Med Phys, 48 (8), 2021.
Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boostArticle de revue
Brachytherapy, 19 (5), 2020.
Impact of a dominant intraprostatic lesion (DIL) boost defined by sextant biopsy in permanent I-125 prostate implants on biochemical disease free survival (bDFS) and toxicity outcomesArticle de revue
Radiother Oncol, 133 , 2019.
Does Seed Migration Increase the Risk of Second Malignancies in Prostate Cancer Patients Treated With Iodine-125 Loose Seeds Brachytherapy?Article de revue
Int J Radiat Oncol Biol Phys, 100 (5), 2018.
High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomesArticle de revue
Radiother Oncol, 124 (1), 2017.
Use of 3D transabdominal ultrasound imaging for treatment planning in cervical cancer brachytherapy: Comparison to magnetic resonance and computed tomographyArticle de revue
Brachytherapy, 16 (4), 2017.
Image-Guided High-Dose-Rate (HDR) Boost Localization Using MRI/MR Spectroscopy: A Correlation Study with BiopsyArticle de revue
Cureus, 8 (9), 2016.
Does prostate volume has an impact on biochemical failure in patients with localized prostate cancer treated with HDR boost?Article de revue
Radiother Oncol, 121 (2), 2016.